MAGELLAN HEALTH INC Form 10-Q April 26, 2018 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10 Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2018

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1 6639

MAGELLAN HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware 58 1076937 (State or other jurisdiction of incorporation or organization) Identification No.)

4800 N. Scottsdale Rd, Suite 4400
Scottsdale, Arizona
(Zip code)

(Address of principal executive offices)

(602) 572 6050

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if

any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non accelerated filer, smaller reporting company, or an emerging growth company. See definition of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b 2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange

Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b 2 of the Exchange Act). Yes No

The number of shares of the registrant's Ordinary Common Stock outstanding as of March 31, 2018 was 24,627,170.

Table of Contents

FORM 10 Q

MAGELLAN HEALTH, INC. AND SUBSIDIARIES

INDEX

		Page No
	PART I — Financial Information:	_
<u>Item 1</u> :	<u>Financial Statements</u>	2
	Consolidated Balance Sheets—December 31, 2017 and March 31, 2018	2
	Consolidated Statements of Income—For the Three Months Ended March 31, 2017 and 2018	3
	Consolidated Statements of Comprehensive Income—For the Three Months Ended March 31,	
	2017 and 2018	4
	Consolidated Statements of Cash Flows—For the Three Months Ended March 31, 2017 and	
	<u>2018</u>	5
	Notes to Consolidated Financial Statements	6
Item 2:	Management's Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3:	Quantitative and Qualitative Disclosures about Market Risk	39
Item 4	Controls and Procedures	40
	PART II — Other Information:	
<u>Item 1</u> :	<u>Legal Proceedings</u>	41
Item 1A:	Risk Factors	41
Item 2:	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	41
Item 3:	<u>Defaults Upon Senior Securities</u>	41
Item 4:	Mine Safety Disclosures	41
<u>Item 5</u> :	Other Information	41
Item 6:	<u>Exhibits</u>	41
Exhibit Index		42
<u>Signatures</u>		43

I

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

MAGELLAN HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

ASSETS		ecember 31,	2	March 31, 018 Unaudited)
Current Assets:				
Cash and cash equivalents (\$229,013 and \$170,575 restricted at				
December 31, 2017 and March 31, 2018, respectively)	\$	398,732	\$	394,326
Accounts receivable, net	Ψ	660,775	Ψ	748,060
Short-term investments (\$219,111 and \$265,112 restricted at		,		,
December 31, 2017 and March 31, 2018, respectively)		310,578		329,710
Pharmaceutical inventory		40,945		37,878
Other current assets (\$41,121 and \$49,939 restricted at December 31, 2017 and		,		,
March 31, 2018, respectively)		72,323		108,872
Total Current Assets		1,483,353		1,618,846
Property and equipment, net		158,638		159,857
Long-term investments (\$17,287 and \$20,811 restricted at December 31, 2017				
and March 31, 2018, respectively)		17,287		20,811
Deferred income taxes		813		1,128
Other long-term assets		22,567		21,489
Goodwill		1,006,288		1,013,313
Other intangible assets, net		268,288		256,293
Total Assets	\$	2,957,234	\$	3,091,737
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current Liabilities:				
Accounts payable	\$	74,300	\$	73,084
Accrued liabilities		193,635		246,909
Short-term contingent consideration		6,892		6,892
Medical claims payable		327,625		390,098
Other medical liabilities		177,002		207,220
Current debt and capital lease obligations		112,849		61,498
Total Current Liabilities		892,303		985,701
Long-term debt and capital lease obligations		740,888		736,688